Laura Trulli

Title: Laura Trulli and Her Patent on Androgen Receptor PROTACs.

Introduction

Laura Trulli is an inventor associated with Madrid, Spain, and GlaxoSmithKline Intellectual Property Development Limited. Her listed patent work concerns PROTAC compounds designed to target the androgen receptor.

Latest Patents

The patent, “Androgen receptor PROTACs,” describes compounds that include 2,4-dioxotetrahydropyrimidinyl derivatives capable of binding cereblon. These PROTACs combine an androgen receptor-binding moiety, a linker, and a cereblon-binding moiety, or degron. The patent also discloses potential medical uses for the compounds. Trulli is credited with 1 patent.

Career Highlights

Trulli’s listed patent contribution focuses on targeted protein degradation, an approach that uses PROTAC molecules to bring a target protein into proximity with cellular machinery involved in its degradation. The disclosed compounds are directed at the androgen receptor.

Collaborations

Christopher Patrick Tinworth is listed as a coworker associated with Trulli’s patent work. The patent is connected with GlaxoSmithKline Intellectual Property Development Limited.

Conclusion

Laura Trulli’s listed invention applies PROTAC technology to androgen receptor targeting, combining a receptor-binding component with a cereblon-binding component and a linker.